Insilico Medicine (03696) rose more than 4% in morning trading. As of press time, the stock was up 4.00% at HK$55.95, with a turnover of HK$264 million.
On the news front, Insilico Medicine (03696) recently issued a voluntary announcement stating that it has entered into a partnership with a frontier foundation model laboratory, with a contract value of up to tens of millions of dollars. The two parties will leverage the MMAI Gym training framework to jointly develop, validate, and commercialize a series of frontier foundation models specifically designed for biological research.
Public information shows that Insilico Medicine (03696) has a cumulative potential total transaction value of approximately US$11 billion, including US$7.3 billion signed year-to-date, accounting for about 7% of all business development deals in China.
Jefferies issued a research report stating that the company expects foundation model capabilities to converge over the next three to five years and remains open to adopting superior third-party models. The long-term investment thesis increasingly depends on converting time advantages into clinically validated drugs, milestones, and licensing deals, rather than maintaining a permanent model advantage.
Comments